Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05023057
Other study ID # 2021-06-040
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 23, 2021
Est. completion date July 2023

Study information

Verified date March 2022
Source Inha University Hospital
Contact Seong Hye Choi, MD, PhD
Phone 82 32 890 3659
Email seonghye@inha.ac.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will be done to investigate the effectiveness of a 24-week multidomain intervention program consisting of cognitive training, exercise, nutrition management, vascular disease risk factor management, social activity, and motivational enhancement on the cognitive function compared to the control group in mild cognitive impairment.


Description:

The physical exercise program will consist of aerobic exercise, exercise to enhance balance and flexibility, muscle-strengthening activities involving major muscle groups, and finger-toe movements. Cognitive training targets the cognitive domains of episodic memory, executive function, attention, working memory, calculation, and visuospatial function. Cognitive training will be conducted using a tablet-based application. Participants will be advised to eat something according to the recommendation of the MIND diet. They will also meet the study nurse every 4 weeks for anthropometric measurements and monitoring of smoking and alcohol intake. The purpose of the motivational enhancement program is to induce, maintain, and strengthen motivation, which is a psychological resource to help maintain dementia prevention activities.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date July 2023
Est. primary completion date June 2023
Accepts healthy volunteers No
Gender All
Age group 60 Years to 79 Years
Eligibility Inclusion Criteria: - 60 to 79 years of age - Having at least one modifiable dementia risk factor - Complaints of cognitive decline by a participant or informant - A performance score that is lower than 1.0 standard deviations below the age-, and education-adjusted normative means for one or more of the delayed recall, naming, visuoconstruction, attention, and executive function tests - MMSE Z score = - 1.5 - Independent activities of daily living - Being able to use the tablet PC through education, or having a person who can help a participant use the tablet PC. - Having a reliable informant who could provide investigators with the requested information - Provide written informed consent Exclusion Criteria: - Major psychiatric illness such as major depressive disorders - Dementia - Other neurodegenerative disease (e.g., Parkinson's disease) - Malignancy within 5 years - Cardiac stent or revascularization within 1 year - Serious or unstable symptomatic cardiovascular disease - Other serious or unstable medical disease such as acute or severe asthma, active gastric ulcer, severe liver disease, or severe renal disease - Severe loss of vision, hearing, or communicative disability - Any conditions preventing cooperation as judged by the study physician - Significant laboratory abnormality that may result in cognitive impairment - Illiteracy - Unable to participate in exercise program safely - Coincident participation in any other intervention trial

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Multidomain intervention
For 24 weeks, participants will receive cognitive training using the tablet PC application twice a week, exercise 3 times a week, nutrition education 12 times, anthropometric measurements and alcohol and smoking monitoring every 4 weeks, motivation reinforcement training 4 times.

Locations

Country Name City State
Korea, Republic of Dong-A University Hospital Busan
Korea, Republic of Chonnam University Hospital Gwangju
Korea, Republic of Inha University Hospital Incheon
Korea, Republic of Bobath Memorial Hospital Seongnam
Korea, Republic of Ewha Womans Seoul Hospital Seoul
Korea, Republic of Konkuk University Hospital Seoul
Korea, Republic of Ajou University Hospital Suwon

Sponsors (1)

Lead Sponsor Collaborator
Inha University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of cognition Repeatable Battery for the Assessment of Neuropsychological Status (range 40-160). Higher scores indicate better performance. Change from Baseline at 24 weeks
Secondary Change of global cognition Mini-Mental State Examination (range 0-30). Higher scores indicate better performance. Change from Baseline at 24 weeks
Secondary Change of function Clinical Dementia Rating scale-Sum of Boxes (range 0-18). Higher scores indicate worse performance. Change from Baseline at 24 weeks
Secondary Change of subjective memory Prospective and Retrospective Memory Questionnaire (range 16-80). Higher scores indicate worse performance. Change from Baseline at 24 weeks
Secondary Change of depression Geriatric Depression Scale-15 items (range 0-15). Higher scores indicate worse performance. Change from Baseline at 24 weeks
Secondary Change of quality of life Quality of life-Alzheimer's disease (range 0-52). Higher scores indicate better performance. Change from Baseline at 24 weeks
Secondary Change of activities of daily living Bayer Activities of Daily Living (range 1-10). Higher scores indicate worse performance. Change from Baseline at 24 weeks
Secondary Change of nutritional behavior Nutrition Quotient for elderly (range 0-100). Higher scores indicate better performance. Change from Baseline at 24 weeks
Secondary Change of nutrition Mini Nutritional Assessment (range 0-14). Higher scores indicate better performance. Change from Baseline at 24 weeks
Secondary Change of motor function Short Physical Performance Battery (range 0-12). Higher scores indicate better performance. Change from Baseline at 24 weeks
Secondary Change of sleep quality Pittsburgh Sleep Quality Index (range 0-21). Higher scores indicate worse performance. Change from Baseline at 24 weeks
Secondary Change of motivation Self Determination Index (SDI). Higher scores of SDI indicate better performance. Change from Baseline at 24 weeks. Higher scores indicate better performance.
See also
  Status Clinical Trial Phase
Completed NCT04513106 - Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial N/A
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Active, not recruiting NCT03167840 - Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment N/A
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Not yet recruiting NCT05041790 - A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment Phase 4
Recruiting NCT04121156 - High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment N/A
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Completed NCT02774083 - Cognitive Training Using Feuerstein Instrumental Enrichment N/A
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Enrolling by invitation NCT06023446 - Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
Completed NCT04567745 - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Phase 1
Recruiting NCT05579236 - Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
Completed NCT03583879 - Using Gait Robotics to Improve Symptoms of Parkinson's Disease N/A
Terminated NCT02503501 - Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease Phase 2
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Active, not recruiting NCT05204940 - Longitudinal Observational Biomarker Study
Recruiting NCT02663531 - Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease N/A
Recruiting NCT06150352 - Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
Recruiting NCT03507192 - Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia. N/A